Imexpharm Corporation · HOSE:IMP
Imexpharm — 8M2024 Earnings Presentation
6 slides from Imexpharm's earnings presentation, September 2024
Slide 1: August and 8M2024 Business Updates
AUGUST AND 8M2024 BUSINESS UPDATES IMEXPHARM CORPORATION
Slide 2: Continued M-o-M growth in revenue and earnings, driven by ETC channel
Continued M-o-M growth in revenue and earnings, driven by ETC channel August net revenue ▪ We continued to experience month- over-month growth, though year- VND 177 bn over-year growth has slowed due to ▲ 11% MoM the strong performance in August ETC ▲ 22% MoM 2023. ▪ ETC maintained its strong revenu
Slide 3: Outperforming market in both ETC and OTC; endeavor to align year-end targets
Outperforming market in both ETC and OTC; endeavor to align year-end targets 8M net revenue ▪ We have achieved VND 1,344 VND 1,344 bn billion in net revenue, representing 57% of our annual ▲ 10% YoY target. We are confident in ETC ▲ 54% YoY delivering our target revenue for the year as revenue tends
Slide 4: Stock performance and business highlights
Stock performance and business highlights Data as of 20 Sep 2024 1. Stock bonus issuance execution ✓Ex-right date: September 17, 2024 ✓Payment ratio: 100% (1:1) IMP DHG ✓Post-issuance charter capital: VND 1,540 bn TRA DBD 2. Organizational restructuring DHT VN-Index ✓To improve supply chain manageme
Slide 5: Disclaimer
Disclaimer The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter. IMP is exempt from a
Slide 6: Thank You
Thank You For further discussion, please contact our IR team [email protected] 6